Atea Completes Patient Enrollment In Phase 3 C-FORWARD Trial In Hepatitis C

Atea Pharmaceuticals completed patient enrollment in its Phase 3 C-FORWARD trial evaluating Bemnifosbuvir and Ruzasvir for hepatitis C virus infection outside North America. Completion of enrollment is a meaningful clinical development and de-risks the trial timeline, though no efficacy or safety data were released. The update is positive for execution but likely limited in immediate market impact absent trial results.

Analysis

Atea Pharmaceuticals completed patient enrollment in its Phase 3 C-FORWARD trial evaluating Bemnifosbuvir and Ruzasvir for hepatitis C virus infection outside North America. Completion of enrollment is a meaningful clinical development and de-risks the trial timeline, though no efficacy or safety data were released. The update is positive for execution but likely limited in immediate market impact absent trial results.